Taizhou, China — April 20, 2026

Space Peptides (Taizhou) Announces Major Manufacturing Capacity Expansion, CRDMO Platform Upgrade and Strategic Entry into Oligonucleotide Sector

On April 2, 2026, Space Peptides (Taizhou) Pharmaceutical Co., Ltd. Board of Directors approved an additional equity investment from existing shareholders Jiangsu Fengtai Chemical and Xiamen Furui’er Pharmaceutical. Over the next five years, Space Peptides (Taizhou) will invest hundreds of millions of USD to upgrade its peptide CRDMO infrastructure while simultaneously building end-to-end oligonucleotide R&D and ramp up manufacturing total solid-phase peptide synthesis capacity to over 70,000 liters and annual output to more than 30 tons.

Today, the company announced a significant expansion of its CRDMO (Contract Research, Development, and Manufacturing Organization) platform alongside its strategic entry into the rapidly growing oligonucleotide therapeutics sector. The move marks a major milestone in the company’s evolution toward becoming a globally integrated service provider across advanced therapeutic modalities.

Driven by surging global demand for peptide-based drugs—particularly oral cyclic peptides and GLP-1 therapies—and the emergence of oligonucleotides as the “third wave” of modern pharmaceuticals, the company is undertaking a multi-year investment initiative to scale capabilities and broaden its technology platform.

“This is a defining moment for our company,” said Dr. Runze He, CEO of Space Peptides (Taizhou). “We are incredibly excited to accelerate our growth through this dual-engine strategy. By expanding our CRDMO platform and entering the oligonucleotide space, we are positioning ourselves to better serve global innovators and to play a meaningful role in shaping the future of advanced therapeutics.”

Comprehensive CRDMO Platform Upgrade

The expansion goes beyond capacity growth, representing a systematic upgrade of the company’s CRDMO capability matrix—from early-stage research through clinical development to large-scale commercial manufacturing.

Key initiatives include:

• R&D Expansion: Enhanced facilities and AI-driven platforms to accelerate peptide sequence design, process development, and analytical validation.
• Production Optimization: Upgrades to existing GMP-compliant production lines to strengthen clinical supply, process validation, and early commercial manufacturing.
• Large-Scale Manufacturing Capacity Ramp-up: Construction of new production buildings (No. 2, 3, and 4), which will increase total solid-phase peptide synthesis capacity to over 70,000 liters and annual output to more than 30 tons.
• Organizational Growth: A new office facility to support expanding teams across project management, regulatory affairs, quality, and commercial operations.

Strategic Entry into Oligonucleotide Therapeutics

In parallel, Space Peptides (Taizhou) is entering the oligonucleotide sector, a fast-growing field encompassing technologies such as siRNA and antisense oligonucleotides (ASO). These therapies offer targeted gene regulation and are unlocking new treatment possibilities across rare diseases, chronic conditions, and CNS disorders.

Leveraging its proprietary AI-driven “Chemical Space” platform and extensive GMP experience, the company will integrate advanced technologies across the full lifecycle of oligonucleotide development and manufacturing.

Positioned for Long-Term Growth

“With our expanding capabilities and growing client demand, we are thrilled to support a rapidly evolving and expanding customer base,” said the company’s Chief Commercial Officer. “This investment allows us to deepen partnerships, deliver greater value, and provide the flexible, high-quality solutions our clients need to succeed.”

Upon completion of Phase II construction, each new production workshop will feature large-scale peptide synthesis reactors (2,000–3,000L), with individual facilities capable of producing 10–12 tons of peptide APIs annually under GMP standards.

Looking Ahead

With its “Peptide + Oligonucleotide” dual-engine strategy, Space Peptides (Taizhou) is building a fully integrated CRDMO platform that spans the entire drug development lifecycle. The company is well positioned to capture growing global demand and strengthen its role as a leading partner in advanced pharmaceutical manufacturing.

About Space Peptides

Space Peptides a CRDMO headquartered in Bern/Switzerland with global manufacturing assets is specialized in the research, development, and manufacturing of high-purity peptides using sustainable and compliant chemical processes. Committed to innovation and environmental stewardship, the company enables partners to achieve regulatory readiness and market leadership through green chemistry solutions.